Drug Cardiomyopathy

Attruby

Payments companies reported to CMS as associated with Attruby. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.3Massociated payments (2023-2025)
6,751clinicians with associated payments
1company reporting

By year

2025 $2.3M

Payments reported as associated with Attruby, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Cardiovascular Disease $965K
Advanced Heart Failure and Transplant Cardiology $918K
Family $66K
Interventional Cardiology $57K
Adult Health (Nurse Practitioner) $48K
Internal Medicine $43K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Attruby

These are the largest totals companies reported as associated with Attruby. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Dmitry Yaranov Memphis, TN Advanced Heart Failure and Transplant Cardiology $79,948.06
Albert Hicks Temple, TX Advanced Heart Failure and Transplant Cardiology $75,581.36
Vasvi Singh Overland Park, KS Cardiovascular Disease $72,672.20
Sabahat Bokhari Allentown, PA Cardiovascular Disease $65,357.32
David Hinchman Boise, ID Cardiovascular Disease $50,979.46
Marcus Urey San Diego, CA Advanced Heart Failure and Transplant Cardiology $44,004.59
Kunjan Bhatt Austin, TX Advanced Heart Failure and Transplant Cardiology $42,050.35
Aasim Afzal Plano, TX Advanced Heart Failure and Transplant Cardiology $38,820.19
David Wolinsky Weston, FL Cardiovascular Disease $35,414.56
Benjamin Horn North Easton, MA Cardiovascular Disease $33,976.53

Prescribed Attruby?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.